A new trading day began on Friday, with Arcutis Biotherapeutics Inc (NASDAQ: ARQT) stock price up 8.61% from the previous day of trading, before settling in for the closing price of $8.94. ARQT’s price has ranged from $1.76 to $13.17 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 303.42% over the last five years. Meanwhile, its annual earnings per share averaged 55.14%. With a float of $99.26 million, this company’s outstanding shares have now reached $115.76 million.
The firm has a total of 296 workers. Let’s measure their productivity.
Arcutis Biotherapeutics Inc (ARQT) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Arcutis Biotherapeutics Inc is 14.26%, while institutional ownership is 100.44%. The most recent insider transaction that took place on Aug 02 ’24, was worth 130,648. Before that another transaction happened on Aug 02 ’24, when Company’s Officer proposed sale 5,220 for $9.02, making the entire transaction worth $47,063.
Arcutis Biotherapeutics Inc (ARQT) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.46 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 55.14% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 9.80% during the next five years compared to -48.07% drop over the previous five years of trading.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Trading Performance Indicators
Here are Arcutis Biotherapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 9.61. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 10.57.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.92, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -1.24 in one year’s time.
Technical Analysis of Arcutis Biotherapeutics Inc (ARQT)
Analysing the last 5-days average volume posted by the [Arcutis Biotherapeutics Inc, ARQT], we can find that recorded value of 2.04 million was lower than the volume posted last year of 3.74 million. As of the previous 9 days, the stock’s Stochastic %D was 47.26%. Additionally, its Average True Range was 0.76.
During the past 100 days, Arcutis Biotherapeutics Inc’s (ARQT) raw stochastic average was set at 44.01%, which indicates a significant decrease from 65.60% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.97% in the past 14 days, which was lower than the 75.77% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.24, while its 200-day Moving Average is $7.09. Now, the first resistance to watch is $9.98. This is followed by the second major resistance level at $10.24. The third major resistance level sits at $10.76. If the price goes on to break the first support level at $9.20, it is likely to go to the next support level at $8.68. Should the price break the second support level, the third support level stands at $8.42.
Arcutis Biotherapeutics Inc (NASDAQ: ARQT) Key Stats
With a market capitalization of 1.12 billion, the company has a total of 115,764K Shares Outstanding. Currently, annual sales are 59,610 K while annual income is -262,140 K. The company’s previous quarter sales were 49,570 K while its latest quarter income was -35,380 K.
